Monitoring Disease Activity: How and When?
Author(s) -
KangMoon Lee
Publication year - 2018
Publication title -
korean journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.203
H-Index - 25
eISSN - 2233-6869
pISSN - 1598-9992
DOI - 10.4166/kjg.2018.71.2.69
Subject(s) - medicine , disease , subclinical infection , inflammatory bowel disease , ulcerative colitis , crohn's disease , gastroenterology , therapeutic approach , gastrointestinal tract , endoscopy , intensive care medicine
Inflammatory bowel disease (IBD) is a chronic, idiopathic inflammatory disease of gastrointestinal tract with waxing and waning clinical course, which may lead to irreversible bowel damage and a loss of bowel function. Cumulative intestinal damage results in complications such as stricture or fistulae, and eventually a large number of IBD patients undergo surgery. Notably, even during remission period (no clinical symptoms), subclinical inflammation often persists and the disease continues to progress. Therefore, the therapeutic target of IBD has been evolving from symptomatic control to mucosal healing to prevent structural intestinal damage. To achieve therapeutic goals in IBD, it is important to optimize therapy according to disease severity and response to treatment. Therefore, monitoring disease activity is recommended throughout the disease course of IBD. Especially strategies to monitor disease beyond symptoms through endoscopy, laboratory markers, and imaging is required.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom